

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * FROST PHILLIP MD ET AL		2. Issuer Name and Ticker or Trading Symbol eXegenics Inc [EXEG]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO & Chariman					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/27/2007						
4400 BISCAYNE BOULEVARD, 15TH FLOOR									
(Street)			4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				
MIAMI, FL 33137									
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	03/27/2007		A		36,518,923	A	(2)		
Common Stock					15,490,546	I			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants (Right to Buy)	\$ 0.6728	03/27/2007		A		3,080,529		(4)	03/27/2017	Common Stock	3,080,529	(2)	3,080,529	I	See Footnote (1)
Warrants (Right to Buy)	\$ 0.8473	03/27/2007		A		3,080,530		(4)	03/27/2017	Common Stock	3,080,530	(2)	3,080,530	I	See Footnote (1)
Warrants (Right to Buy)	\$ 1.0466	03/27/2007		A		3,080,530		(4)	03/27/2017	Common Stock	3,080,530	(2)	3,080,530	I	See Footnote (1)
Warrants (Right to Buy)	\$ 0.4984	03/27/2007		A		4,000,000		(4)	03/27/2017	Common Stock	4,000,000	(5)	4,000,000	I	See Footnote (3)
Warrants (Right to Buy)	\$ 0.0002	03/27/2007		A		81,085		(4)	01/11/2017	Common Stock	81,085	(6)	81,085	I	See Footnote (3)
Warrants (Right to Buy)	\$ 38.54	03/27/2007		A		6,487		(4)	01/11/2017	Common Stock	648,700	(6)	6,487	I	See Footnote (3)
Warrants (Right to Buy)	\$ 0.672	03/27/2007		A		22,124		(4)	03/27/2017	Common Stock	22,124	(6)	22,124	I	See Footnote (3)
Warrants (Right to Buy)	\$ 0.8473	03/27/2007		A		22,124		(4)	03/27/2017	Common Stock	22,124	(6)	22,124	I	See Footnote (3)
Warrants (Right to Buy)	\$ 1.0467	03/27/2007		A		22,125		(4)	03/27/2017	Common Stock	22,125	(6)	22,125	I	See Footnote (3)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

FROST PHILLIP MD ET AL 4400 BISCAYNE BOULEVARD 15TH FLOOR MIAMI, FL 33137	X	X	CEO & Chariman	
--	---	---	----------------	--

Signatures

/s/ Phillip Frost, M.D.		03/29/2007
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The securities are held by Frost Gamma Investments Trust, of which Phillip Frost, M.D., is the trustee. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma, L.P. The general partner of Frost Gamma, L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (1) Frost Gamma Investment Trust acquired these securities in connection with the merger of Froptix Corporation into a wholly-owned subsidiary of the issuer in exchange for securities of Froptix held by Frost Gamma Investment Trust immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was \$3.28.
- These securities are owned directly by The Frost Group, LLC. Frost Gamma Investments Trust is a principal member of The Frost Group. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (2) These warrants are immediately exercisable.
- (3) These warrants were acquired by The Frost Group as part of the consideration paid by the issuer for a line of credit extended by The Frost Group to the issuer in connection with the merger.
- (4) The Frost Group acquired these securities in connection with the merger of Acuity Pharmaceuticals, Inc. into a wholly-owned subsidiary of the issuer in exchange for securities of Acuity held by The Frost Group immediately before the merger. On the effective date of the merger the closing sales price of the issuer's common stock was \$3.28 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.